ImmuneOncia Therapeutics is focused on developing innovative immunotherapies aimed at harnessing the body's immune system to combat cancer. Their lead product, IMC-001, is a fully human anti-PD-L1 monoclonal antibody designed to block the PD-L1 protein, which is often overexpressed on tumor cells and immune cells within the tumor microenvironment. By inhibiting PD-L1, IMC-001 aims to reactivate T-cell activity, thereby enhancing the immune response against tumors. The antibody has shown promising safety and efficacy results in early clinical studies, and it is currently undergoing a multi-regional Phase II study in Korea and China.

Another key product in ImmuneOncia's pipeline is IMC-002, an anti-CD47 monoclonal antibody engineered to avoid binding to red blood cells, which can lead to adverse effects such as anemia. CD47 is a protein that cancer cells often exploit to evade immune detection by sending a "don't-eat me" signal to macrophages. By blocking the interaction between CD47 and its receptor SIRPα, IMC-002 aims to restore the phagocytic activity of macrophages against cancer cells. This product has recently received FDA clearance for a Phase I study in the U.S. for solid tumors and lymphomas. The company is also exploring the potential of combining IMC-001 and IMC-002 to enhance anti-tumor effects, alongside developing additional antibodies targeting novel immune checkpoints.

South Korea

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide.

ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 Phase I study was completed in Feb 2019 and its Phase 2 study is being prepared. ImmuneOncia is also developing several antibodies targeting novel immune-checkpoints.

ImmuneOncia Therapeutics

Company Details